Loading...
•
Dec 31, 2022
Kiniksa Q4 2022 Earnings Report
Kiniksa reported Q4 2022 financial results with ARCALYST net product revenue of $39.9 million.
Key Takeaways
Kiniksa Pharmaceuticals reported fourth quarter and full-year 2022 financial results. The company is focused on increasing brand awareness of ARCALYST and pursuing collaborative study agreements for mavrilimumab. They are advancing the Phase 2 trial of KPL-404 in rheumatoid arthritis and expect data in the first half of 2024.
ARCALYST Q4 2022 net product revenue was $39.9 million.
ARCALYST full-year 2022 net product revenue was $122.5 million.
ARCALYST full-year 2023 net product revenue is expected to be $190 - $205 million, representing >60% year-over-year growth at the midpoint.
Cash reserves are expected to fund operations into at least 2025.
Revenue by Segment
Forward Guidance
Kiniksa expects ARCALYST full-year 2023 net product revenue to be between $190 million and $205 million.
Positive Outlook
- ARCALYST full-year 2023 net product revenue expected to be $190 - $205 million, representing >60% year-over-year growth at the midpoint
- Advancing Phase 2 trial of KPL-404 in rheumatoid arthritis
- Expect data from KPL-404 trial in the first half of 2024
- Pursuing collaborative study agreements for mavrilimumab in rare cardiovascular diseases
- Cash reserves expected to fund operations into at least 2025
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...